Skip to content
Home/Companies/Pharma/Presidio Pharmaceuticals

Presidio Pharmaceuticals

Pharma·United States·Active·8yr hold
Entry
2018
Hold
8yr
Status
Active

Who owns Presidio Pharmaceuticals?

Presidio Pharmaceuticals is currently owned by Sobera Capital through Sobera Capital Fund IV (2017 vintage), since 2018.

Hand-verified · updated 2026-08-10

Sobera Capital
Investor
Sobera Capital
Sobera Capital Fund IV · 2017 · Secondaries

Key facts

HQUnited States
SectorPharma
StatusActive

More from Sobera Capital Fund IV

Other portfolio companies in the same fund.

Axellis
Exited 2022
MedTechUnited Kingdom· 2018
EffRx Pharmaceuticals
EffRx Pharmaceuticals
Exited 2023
PharmaSwitzerland· 2018
to
M.O.R.E Medical Solutions
Active
MedTechGermany· 2018
Memo Therapeutics
Memo Therapeutics
Exited 2026
BiotechSwitzerland· 2018
to
MyoScience
Exited 2019
MedTechUnited States· 2018
to
Panoratio
Exited 2021
Data & AnalyticsGermany· 2015

More PE-backed in Pharma

Comparable pharma deals from other GPs.

Laboratoires Delbert
Active
SocadifFrance
AMW
AMW
Active
SHS Gesellschaft für BeteiligungsmanagementGermany· 2026
Basic Pharma
Active
SHS Gesellschaft für BeteiligungsmanagementNetherlands· 2026
Cinclus Pharma
Cinclus Pharma
Active
Claret Capital PartnersSweden· 2026
InfoRLife
Active
BC PartnersSwitzerland· 2026
IRAB
IRAB
Active
ARCHIMEDSpain· 2026
Track Presidio Pharmaceuticals

Save this record to your watchlist and pick up your research where you left off. No spam.

Create free account

Get the full record on Presidio Pharmaceuticals.

Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.

Hand-checked deal notes on this investment
Save this company to your watchlist
Exit buyers and MOIC on realized deals (Pro)
or
Continue with email

Already a member? Sign in

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue